|
|
6900 Dumbarton Cr
Fremont, CA 94555-3651 USA
phone:(510) 284-3000
fax:(510) 284-3100
|
|
| Symbol |
GTOP |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.genitope.com/
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Genitope is a biotech company focused on novel immunotherapies for the treatment of cancer. |
|
| Management |
| Dan W. Denney, Jr., Ph.D., Founder, Chief Executive Officer and Chairman of the Board; Michael J. Buckley, Ph.D., Vice President of Manufacturing; Thomas DeZao, Vice President of Strategic Marketing and Sales; Claude Miller, Vice President of Regulatory Affairs and Quality;
David Miller, Vice President of Information Technology; Mary Ellen Rybak, M.D., Vice President of Medical Affairs; Thomas Theriault, Ph.D., Vice President of Research and Development; John Vuko, Vice President and Chief Financial Officer; Laura Woodhead, Vice President of Legal Affairs |
| |
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Genitope Corporation is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Immunotherapies are treatments that utilize the immune system to combat diseases. The Company's lead product candidate, MyVax personalized immunotherapy, is a patient-specific active immunotherapy that is based on the unique genetic makeup of a patient's tumor and is designed to activate a patient's immune system to identify and attack cancer cells. MyVax is in a pivotal Phase III clinical trial and additional Phase II clinical trials for the treatment of B-cell non-Hodgkin's lymphoma. The Company is also developing MyVax for the treatment of chronic lymphocytic leukemia. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
